Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that new preclinical data supporting the clinical development of its proprietary next generation antibody-drug conjugate (ADC) and innovative tetraspecific ANKET®will be presented at the SITC Annual Meeting 2024.
“We are thrilled to share our latest preclinical data at the SITC Annual Meeting, highlighting the potential of IPH6501, our tetra-specific NK cell engager and IPH4502, our innovative ADC targeting Nectin-4. These findings underscore our commitment to advancing next-generation immunotherapies and reflect significant progress in the development of our drug candidates. We look forward to engaging with the scientific community as we continue to push the boundaries of next generation immunotherapies,” commentedPr. Eric Vivier, Chief Scientific Officer of Innate Pharma.
******
Details of the presentations
Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | 6-10 November, Houston, Texas and Virtual
Harnessing NK Cells in Cancer TherapiesSession 107d: NK Cells and Innate ImmunityPresentation Type: Oral PresentationPresentation Date and Time: Friday, Nov. 8, 2024, 4:35pm CSTSpeaker: Eric Vivier, Chief Scientific Officer, Innate Pharma (co-chair of the session)
- Preclinical Characterization of IPH6501: A Novel IL2v-Armed Tetraspecific NK Cell Engager Targeting CD20 in Relapsed or Refractory B cell Non-Hodgkin Lymphoma Subtypes and Post-CAR-T Therapy.Abstract Number: 1083Presentation Type: Poster PresentationPrimary Category: Immuno-Conjugates and Chimeric MoleculesPoster Presentation Day: Friday, Nov. 8, 2024
- IPH45, a next-generation antibody-drug conjugate (ADC) targeting Nectin-4Abstract Number: 1056Presentation Type: Poster PresentationPrimary Category: Immuno-Conjugates and Chimeric MoleculesPoster Presentation Day: Saturday, Nov. 9, 2024
More information can be found on theJITC website.
Protein & Antibody Engineering Summit (PEGS) Europe | 5-7 November, Barcelona, Spain and Virtual
In addition, the presentation entitled "A Next-Generation ADC for Nectin-4 Expressing Tumours: Preclinical Characterisation of IPH45, a Novel and Differentiated Exatecan-Based ADC Targeting Nectin-4" was presented at the PEGS Europe Summit. The presentation is available on the Company website, in thepublications section.
******
About IPH4502
IPH4502 is a novel topoisomerase I inhibitor Antibody Drug Conjugate (ADC) conjugated to exatecan targeting Nectin-4.Nectin-4 is a cell membrane adhesion protein overexpressed in several solid tumors, including urothelial, breast, lung, ovarian, and pancreatic cancers, with limited expression in normal tissues.
In non-clinical models, IPH4502 is well tolerated and shows anti-tumor efficacy in vitro and in vivo.In September 2024, the U.S Food and Drug Administration cleared Innate’s investigational new drug (IND) application to initiate a Phase 1 clinical study of IPH4502 in Nectin-4 expressing solid tumor indications.
About IPH6501
IPH6501 is the first Antibody-based NK cell Engager Therapeutic to co-engage activating receptors on NK cells (NKp46 and CD16), IL-2R (but not a subunit) through a variant of human IL-2, and a tumor antigen (CD20) via a single molecule, hence providing proliferation and activation signals targeted to NK cells and promoting their cytotoxic activity against CD20 expressing malignant cells.
IPH6501 has shown better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models (Demaria, EHA 2023).
IPH6501 is currently being evaluated in a Phase 1/2 multicenter trial (NCT06088654), investigating the safety and tolerability of IPH6501 in patients with Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin’s Lymphoma.
| Press release in English | 277.26 KB |
| Communiqué de presse en français | 204.26 KB |